Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade
Mehdi Touat, … , Jean-Charles Soria, Sophie Postel-Vinay
Mehdi Touat, … , Jean-Charles Soria, Sophie Postel-Vinay
Published February 15, 2018
Citation Information: J Clin Invest. 2018;128(4):1671-1687. https://doi.org/10.1172/JCI90277.
View: Text | PDF
Research Article Oncology

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

  • Text
  • PDF
Abstract

Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non–small-cell lung cancer (NSCLC), making this DNA repair protein an attractive target for exploiting synthetic lethal approaches in the disease. Using unbiased proteomic and metabolic high-throughput profiling on a unique in-house–generated isogenic model of ERCC1 deficiency, we found marked metabolic rewiring of ERCC1-deficient populations, including decreased levels of the metabolite NAD+ and reduced expression of the rate-limiting NAD+ biosynthetic enzyme nicotinamide phosphoribosyltransferase (NAMPT). We also found reduced NAMPT expression in NSCLC samples with low levels of ERCC1. These metabolic alterations were a primary effect of ERCC1 deficiency, and caused selective exquisite sensitivity to small-molecule NAMPT inhibitors, both in vitro — ERCC1-deficient cells being approximately 1,000 times more sensitive than ERCC1-WT cells — and in vivo. Using transmission electronic microscopy and functional metabolic studies, we found that ERCC1-deficient cells harbor mitochondrial defects. We propose a model where NAD+ acts as a regulator of ERCC1-deficient NSCLC cell fitness. These findings open therapeutic opportunities that exploit a yet-undescribed nuclear-mitochondrial synthetic lethal relationship in NSCLC models, and highlight the potential for targeting DNA repair/metabolic crosstalks for cancer therapy.

Authors

Mehdi Touat, Tony Sourisseau, Nicolas Dorvault, Roman M. Chabanon, Marlène Garrido, Daphné Morel, Dragomir B. Krastev, Ludovic Bigot, Julien Adam, Jessica R. Frankum, Sylvère Durand, Clement Pontoizeau, Sylvie Souquère, Mei-Shiue Kuo, Sylvie Sauvaigo, Faraz Mardakheh, Alain Sarasin, Ken A. Olaussen, Luc Friboulet, Frédéric Bouillaud, Gérard Pierron, Alan Ashworth, Anne Lombès, Christopher J. Lord, Jean-Charles Soria, Sophie Postel-Vinay

×

Figure 4

Exquisite sensitivity to NAMPT inhibition is a primary effect of ERCC1 deficiency.

Options: View larger image (or click on image) Download as PowerPoint
Exquisite sensitivity to NAMPT inhibition is a primary effect of ERCC1 d...
(A) Representative Western blot of NAMPT and ERCC1 protein expression and (B) survival experiment on FK866 exposure according to the reintroduction of the 4 alternative ERCC1 isoforms. (C) Survival experiment on FK866 exposure of the H1975 ERCC1-isogenic model. (D) Survival experiment on GNE-617 exposure of the A549 ERCC1-isogenic model. (E and F) Rescue of FK866 toxicity by the administration of nicotinamide mononucleotide (NMN) 100 μM in the H1975 (E) and A549 (F) ERCC1-isogenic models. Data for B–F are mean surviving fraction ± SD from 1 experiment. (G) Cell viability after acute NAMPT silencing by siRNA in A549 ERCC1-proficient and ERCC1-deficient cells. Toxicity of PLK1 silencing by siRNA was used as a positive control for cell death induction. Data are mean viability ± SD from 1 representative experiment. Statistical analyses are indicated (Mann-Whitney U test corrected for multiple comparisons). NS indicates no statistically significant difference. (H) Representative Western blot of NAMPT and ERCC1 protein expression after NAMPT silencing by siRNA in A549 ERCC1-proficient and ERCC1-deficient cells. For A–H, data were replicated in at least 3 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts